Novel Imaging Tracer May Have Promise in Alzheimer’s PET scans targeting SV2A assess synaptic density, small study suggests
Positron Emission Tomography (PET) scanning with the compound 11C-UCB-J may provide a direct measure of synaptic density and may be a novel in vivo biomarker for Alzheimer’s and outcome measure for drug trials, reported Ming-Kai Chen, MD, of Yale University in New Haven, Conn., and colleagues in JAMA Neurology. {read more here}
By tracing the progression of nerve damage and the progression of potential causes of that damage, the radioligands can also be used to test the efficacy of new treatments to protect the neurons that regulate the activity of the patients’ hearts. {read more here}
Through a combination of PET and MRI, Canadian researchers are developing a way to deliver personalized treatment to patients with neurological diseases and better predict their therapeutic response, according to a study published online June 14 in NeuroImage. {read more here}
Carbon-11 (C-11) PET that targets translocator protein (TSPO) expression in the joint lining tissue of the knee may be a better way to determine the extent of rheumatoid arthritis (RA), according to a study published in the July issue of the Journal of Nuclear Medicine. {read more here}